Skip to main content

NCBiotech News

  • A family-owned German company called Raumedic has opened a $27 million development and production facility in western North Carolina to make medical and pharmaceutical plastic and rubber components.
  • Blood therapeutics company Grifols said it will invest $210 million to build two new facilities at its Clayton campus.
  • The federal faucet is opening again to pour $25.5 million into solithromycin, a promising drug being developed by Cempra, a Chapel Hill company that has declared war on bacterial infections.  
  • Durham-based BioCryst Pharmaceuticals might have a Zika bazooka on its hands, because the company’s experimental broad spectrum antiviral drug BCX4430 saved the lives of a batch of lab mice whose immune systems were deliberately suppressed before they were infected with Zika virus.
  • OncoTAb, a Charlotte company developing cancer diagnostics technologies with help from a North Carolina Biotechnology Center loan, is the only North Carolina life science company among the 60 startups and emerging companies have made the cut to present at this year’s Southeast Venture Conference.
  • NCBiotech President and CEO Doug Edgeton did some prognosticating at a luncheon briefing preceding Tuesday’s opening of the two-day 2016 CED Life Science Conference at the Raleigh Convention Center, presented each year by CED in partnership with NCBiotech and NCBio.
  • Leaders of four NCSU life science spinouts shared their growing pains and triumphs with more than 100 people gathered in a ballroom at the Raleigh Convention Center during a pre-conference panel discussion to kick off the 2016 CED Life Science Conference.
  • Innovate Biopharmaceuticals of Raleigh has completed an agreement to license all of Alba Therapeutics’ assets relating to larazotide acetate, a drug candidate progressing toward phase three clinical trials for the treatment of celiac disease.
  • West Pharmaceutical Services, a global designer and manufacturer of pharmaceutical packaging and delivery systems, will invest $19 million to upgrade its production plant in Kinston.
  • Precision BioSciences, a 2006 Duke University spin-out with a unique method to target and alter DNA, has signed a development deal with Baxalta that could bring the Research Triangle Park biotechnology company up to $1.6 billion.
  • Durham-based Bioventus has signed a multi-year agreement with IBSA (Institut Biochimique SA), a Swiss pharmaceutical company, to secure the exclusive U.S. distribution rights for GELSYN-3, a three-injection, hyaluronic acid product for pain relief from osteoarthritis of the knee.
  • North Carolina voters will not only cast ballots for their favorite presidential candidate in the March 15 primary election. They will also decide a $2 billion state bond referendum that has long-term implications for North Carolina’s life science community.
  • Severe weather is causing problems across North Carolina. For Wednesday, Feb. 24, 2016, NCBiotech reports the following changes to normal office hours:
  • Chapel Hill gene therapy startup Bamboo Therapeutics raised a whopping $49.5 million from six investors, to advance its battle against childhood neurological diseases.
  • NCBiotech will inaugurate a quarterly Life Sciences Forum series on Monday, February 29, with a panel discussion designed to reinforce how venture philanthropy can, and does, play an increasingly significant role in life science product development.
  • Bioscience briefs with names making news
  • SoBran BioScience, a 500-employee contract research organization based in Fairfax, Va., will open a new animal research facility this summer in Greensboro.
  • Chapel Hill bioscience company BioKier has received a $1.6 million grant from the National Institutes of Health to advance development of the company’s unique approach to treating Type 2 diabetes, also known as noninsulin-dependent diabetes.
  • It wasn’t always Syngenta. And if regulators approve this week’s $43 billion buyout offer from Chinese state-owned China National Chemical Corp., aka ChemChina, it’s likely to remain in North Carolina, but it won’t be Syngenta much longer.
  • Cempra, a Chapel Hill company that’s developing antibiotics to treat bacterial infections, has signed a deal with a Massachusetts firm to streamline the production process for Cempra’s lead drug candidate, solithromycin.

Pages

Subscribe to News & Events